Panzara Michael A. 4

What Happened
Michael A. Panzara, Chief Medical Officer of Immunic, Inc. (IMUX), was granted 300,000 derivative shares (an option award) on April 24, 2026. The Form 4 reports an acquisition price of $0.00 and a reported value of $0 for the transaction; the award is a time-vested equity grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-24; Form filed: 2026-04-29 (filed five days after the transaction; may be late relative to the typical two-business-day Form 4 deadline).
• Shares/units granted: 300,000 (reported as a derivative/security award). Reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The options are time-vested — 50% vest on April 24, 2027; the remaining 50% vests in 24 equal monthly installments thereafter, subject to continued employment in good standing.

Context
This is a compensation-style option grant (not a purchase or sale). Time-based vesting means the award becomes usable only if the reporting person remains employed through the vesting dates; it does not represent immediate liquidity. The later filing date may be noteworthy because insiders generally must report Form 4 transactions within two business days.